Mok, T. S., Solomon, B. J., Felip, E., Bauer, T. M., Liu, G., Goto, Y., Wu, Y., Soo, R. A., Mazières, J., Marinis, F. D., Kim, D., Wang, I., Paolini, J., Polli, A., Rifi, N., Toffalorio, F., Shaw, A. T. (2026). Lorlatinib vs crizotinib as first-line treatment for advanced
                    <i>ALK</i>
                    + non-small cell lung cancer: 7-year update from the phase 3 CROWN study.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.8502